Not yet recruiting
AAV9-ASAH1 intracisterna magna Gene Therapy (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA - PME)
2026-527323-10-00· Phase 1/2· Genethon· Source
Recruiting
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source
Recruiting
A Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
2024-520125-36-00· Phase 1· AbbVie Deutschland GmbH & Co. KG· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Active, not recruiting
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
NCT07134088· Phase 1/2· Amgen· Source
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
NCT07038824· Phase 1/2· Entrada Therapeutics, Inc.· Source
Recruiting
Study to evaluate efficacy and safety of inclisiran in children aged 2 to under 12 years of age with homozygous familial hypercholesterolemia
2024-514595-41-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
NCT07037862· Phase 1/2· Entrada Therapeutics, Inc.· Source
Active, not recruiting
Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterolemia.
2024-514594-21-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301· Phase 1/2· University of Birmingham· Source
Active, not recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
2023-507655-30-00· Phase 3· Eli Lilly & Co.· Source
Enrolling by invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315· Phase 3· Sanofi· Source
Active, not recruiting
A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma
2022-502984-39-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171· Phase 2· Pfizer· Source
Active, not recruiting
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855· Phase 3· Scholar Rock, Inc.· Source
Active, not recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035· Phase 3· PedAL BCU, LLC· Source
Recruiting
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
NCT05384821· Phase 1/2· Centre Oscar Lambret· Source
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326· Phase 3· Eli Lilly and Company· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Recruiting
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· Phase 3· GPOH gGmbH· Source
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2) - NIVO ALCL
2024-516807-17-00· Phase 2· Institut Gustave Roussy· Source
Active, not recruiting
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
NCT03643133· Phase 2· UNICANCER· Source
Active, not recruiting
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
NCT03793478· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
2023-504880-18-00· Phase 1/2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy of GIVINOSTAT in all the patients affected with Duchenne Muscolar Dystrophy who have been already treated in one of the GIVINOSTAT studies in the past
2023-504520-26-00· Phase 3· Italfarmaco S.p.A.· Source
Recruiting
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT02813135· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
NCT02724163· Phase 3· University of Birmingham· Source
Active, not recruiting
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT00470223· Phase 3· UNICANCER· Source